Remote robot-assisted laparoscopic surgery for gynecological cancer treatment
Exploratory Study on the Application of Laparoscopic Surgical Systems for Gynecological and Remote Surgical Treatment.
This study is testing if remote robot-assisted surgery using a 5G network can effectively treat women with gynecological cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | Affiliated Hospital of Nantong University Academic / other |
| Locations | 1 site (Nantong, Jiangsu) |
| Trial ID | NCT06676267 on ClinicalTrials.gov |
What this trial studies
This clinical study explores the use of remote robot-assisted laparoscopic surgery for treating gynecological cancer through a 5G network. It follows a prospective, single-center, single-arm exploratory design, involving three phases: screening, treatment, and follow-up. During the screening phase, eligible patients will be identified and consented, followed by the treatment phase where the surgery will be performed using advanced laparoscopic systems. The follow-up phase will monitor patients for safety and effectiveness up to one month post-surgery.
Who should consider this trial
Good fit: Ideal candidates are patients requiring endoscopic surgery for gynecological conditions who can provide informed consent.
Not a fit: Patients with advanced-stage cancer (clinical stage IV) or those requiring emergency surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance surgical outcomes and accessibility for patients with gynecological cancer.
How similar studies have performed: While the use of robotic surgery is established, the specific application of 5G technology in this context is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who require endoscopic surgery * Voluntarily participate in this study and sign informed consent in writing Exclusion Criteria: * Patients with malignant tumors with clinical stage IV * Those who require emergency surgery * Presence of active bleeding, severe abnormal coagulopathy (prothrombin time (PT) or international normalized ratio (INR) greater than 1.5 times the upper limit of normal), or platelet count \< 80×10\^9/L * Patient has severe cardiovascular or circulatory disease and cannot tolerate surgery * Participated in other clinical trials in the past 1 month * Inability to understand trial requirements, or inability to complete the study follow-up plan * Other conditions that are considered by the investigator to be inappropriate for enrollment
Where this trial is running
Nantong, Jiangsu
- Affiliated Hospital of Nantong University — Nantong, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Minhui Hua, M.D. — Affiliated Hospital of Nantong University
- Study coordinator: Minhui Hua, M.D.
- Email: mh_hua@ntu.edu.cn
- Phone: 13773631198
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.